论文部分内容阅读
降低复方口服避孕药(COC)中雌激素剂量是目前激素类避孕药研究的一个新方向,和含标准剂量雌激素的COC相比,含极低剂量雌激素的COC与其周期控制差别甚微。在短期安全性方面,恶心、呕吐、腹痛、乳房胀痛及头痛等不良反应的发生率明显下降;在长期安全性方面,含极低剂量雌激素的COC对卵巢癌、子宫内膜癌是否有更好的保护作用尚待进一步观察。有循环系统疾病危险因素的妇女服用含极低剂量EE的COC亦有理论上的优势。
Reducing the dosage of estrogen in compound oral contraceptives (COCs) is a new direction in the research of hormonal contraceptives. Compared with the COCs containing standard estrogen, COCs containing very low doses of estrogen have little difference with their cycle control. In short-term safety, the incidence of nausea, vomiting, abdominal pain, breast pain and headache and other adverse reactions decreased significantly; in the long-term safety, with very low doses of estrogen COC on ovarian cancer, endometrial cancer is there Better protection remains to be seen. Women who have circulatory system risk factors also have theoretical advantages in taking COCs with very low doses of EE.